Raloxifene is prescribed to a postmenopausal patient to prevent which condition?

Raloxifene is primarily used to prevent and treat osteoporosis in postmenopausal women, and it is also indicated for reducing the risk of invasive breast cancer in certain populations, particularly those at high risk. It works as a selective estrogen receptor modulator (SERM), meaning it can act like estrogen in some tissues, particularly in bone and breast tissues. By mimicking the effects of estrogen in bone, it helps to maintain bone density and reduce the risk of fractures. Concurrently, by blocking estrogen's effects in breast tissue, it contributes to a decreased risk of developing breast cancer.

While other options might refer to important health issues, they do not directly relate to the specific mechanism and indications of raloxifene use. For example, cardiovascular diseases and diabetes are not the primary focus of treatment with raloxifene, and chronic hypertension is primarily managed through different classes of medications that directly target blood pressure regulation. Hence, the option highlighting breast cancer aligns with raloxifene's intended use and therapeutic action.